Free Trial

Edesa Biotech Q1 2025 Earnings Report

Edesa Biotech logo
$2.50 -0.03 (-1.19%)
As of 03/28/2025 04:00 PM Eastern

Edesa Biotech EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.17
One Year Ago EPS
-$0.54

Edesa Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Edesa Biotech Announcement Details

Quarter
Q1 2025
Time
After Market Closes

Conference Call Resources

Remove Ads

Edesa Biotech Earnings Headlines

Edesa Biotech files to sell 7.81M common shares for holders
EDSA: Raises $15 Million to Advance EB06…
Game Over for Tesla?
Tesla is down 50% from its high... Our research indicates investors are waking up to the fact that Tesla is no longer Musk's #1 priority. His real goal is political power - and his private AI firm xAI. He recently bought over $1 billion worth of AI chips from NVIDIA... And is about to spend $5 billion on yet another data center for xAI.
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
See More Edesa Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email.

About Edesa Biotech

Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

View Edesa Biotech Profile

More Earnings Resources from MarketBeat